user

Lipid Effects and Cardiovascular Disease Risk Associated with Glucose-Lowering Medications

被引：2
|
作者：
Staehli, Barbara E. [1 ]
Gebhard, Catherine [1 ]
Tardif, Jean-Claude [1 ,2 ]
机构：
[1] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada
[2] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada
来源：
CURRENT CARDIOLOGY REPORTS | 2015年 / 17卷 / 07期
关键词：
Diabetes; Glucose-lowering medications; Lipids; Cardiovascular diseases; Metformin; Insulin secretagogues; Thiazolidinediones; Alpha-glucosidase inhibitors; Glucagon-like peptide-1 agonists; DPP-4; inhibitors; SGLT2; Insulin; TYPE-2; DIABETES-MELLITUS; GLUCAGON-LIKE PEPTIDE-1; CORONARY-ARTERY-DISEASE; INTIMA-MEDIA THICKNESS; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; RANDOMIZED CLINICAL-TRIALS; IMPROVES GLYCEMIC CONTROL; LONG-TERM EFFICACY; HEART-FAILURE; MYOCARDIAL-INFARCTION;
D O I：
10.1007/s11886-015-0608-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Diabetes is a global epidemic, associated with a high burden of complications and 4.6 million deaths annually worldwide. As a result of decreasing levels of physical activity and increasing rates of obesity, diabetes is shifting from a disease affecting the elderly to one that affects younger patients or even children. Thus, aggressive treatment and optimal control of risk factors is the key to improve outcomes in those patients. Accumulating evidence of the cardiovascular and lipid effects of glucose-lowering medications suggest that treatment efficacy in diabetes can be further improved. This review provides an overview of the lipid effects and cardiovascular disease risk of current anti-diabetic medications and highlights opportunities and challenges in clinical practice.
引用
收藏
页数：9
相关论文
共 50 条
  • [1] Lipid Effects and Cardiovascular Disease Risk Associated with Glucose-Lowering Medications
    Barbara E. Stähli
    Catherine Gebhard
    Jean-Claude Tardif
    [J]. Current Cardiology Reports, 2015, 17
  • [2] The impact of glucose-lowering medications on cardiovascular disease
    Avogaro, Angelo
    De Kreutzenberg, Saula Vigili
    Fadini, Gian Paolo
    [J]. CARDIOVASCULAR ENDOCRINOLOGY & METABOLISM, 2018, 7 (01): : 13 - 17
  • [3] Glucose-Lowering Medications and Cardiovascular Outcomes
    Madhan Shanmugasundaram
    J. R. Exequiel Pineda
    Sangeetha Murugapandian
    [J]. Current Cardiology Reports, 2021, 23
  • [4] Glucose-Lowering Medications and Cardiovascular Outcomes
    Shanmugasundaram, Madhan
    Pineda, J. R. Exequiel
    Murugapandian, Sangeetha
    [J]. CURRENT CARDIOLOGY REPORTS, 2021, 23 (04)
  • [5] Perspectives on Some Controversies in Cardiovascular Disease Risk Assessment in the Pharmaceutical Development of Glucose-Lowering Medications
    Hoogwerf, Byron J.
    Manner, David H.
    Fu, Haoda
    Moscarelli, Elena
    Gaydos, Brenda L.
    Heine, Robert J.
    [J]. DIABETES CARE, 2016, 39 : S219 - S227
  • [6] Cardiovascular outcome trials of glucose-lowering medications: an update
    Home, Philip
    [J]. DIABETOLOGIA, 2019, 62 (03) : 357 - 369
  • [7] ANALYSIS OF CARDIOVASCULAR SAFETY OF NOVEL GLUCOSE-LOWERING MEDICATIONS
    Mkrtumyan, A. M.
    Markova, T. N.
    Mishchenko, N. K.
    [J]. KARDIOLOGIYA, 2019, 59 (07) : 76 - 83
  • [8] Cardiovascular outcome trials of glucose-lowering medications: an update
    Philip Home
    [J]. Diabetologia, 2019, 62 : 357 - 369
  • [9] Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
    Patti, Angelo Maria
    Rizvi, Ali A.
    Giglio, Rosaria Vincenza
    Stoian, Anca Pantea
    Ligi, Daniela
    Mannello, Ferdinando
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
  • [10] Methods Issues in Observational Studies of the Cardiovascular Risk Associated with Glucose-Lowering Medications: Results of a Systematic Review and Evaluation
    Riera-Guardia, Nuria
    Margulis, Andrea V.
    Pladevall, Manel
    Varas-Lorenzo, Cristina
    Perez-Gutthann, Susana
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 80 - 81
12345